国内外学术动态

第5版世界卫生组织造血淋巴肿瘤MDS和AML分类更新解读

展开
  • 1.浙江大学附属第四医院检验科,浙江 义乌 322000
    2.云康血液病整合诊断中心,广东 广州 510700
叶向军 E-mail: toyxj@zju.edu.cn

收稿日期: 2023-03-07

  网络出版日期: 2024-03-15

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML

Expand
  • 1. Department of Laboratory Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Yiwu 322000, China
    2. Yunkang Hematologic Diseases Integrated Diagnosis Center, Guangdong Guangzhou 510700, China

Received date: 2023-03-07

  Online published: 2024-03-15

摘要

基于修订的第4版世界卫生组织(World Health Organization,WHO)造血淋巴肿瘤分类之后相关领域积累的研究成果和临床应用进展,WHO在2022年提出了第5版造血淋巴肿瘤分类(以下简称第5版分类)。第5版分类中骨髓增生异常性肿瘤/综合征(myelodysplastic neoplasms/syndrome,MDS)和急性髓系白血病(acute myeloid leukemia,AML)与第4版分类有较大更新,在临床实践中对疾病诊断和治疗,乃至疾病登记、科研等都具有重要意义。本文根据发表于Leukemia杂志出版的第5版分类和国际癌症研究机构官方网站上发布的第5版分类测试版进行解读。

本文引用格式

叶向军, 卢兴国 . 第5版世界卫生组织造血淋巴肿瘤MDS和AML分类更新解读[J]. 诊断学理论与实践, 2023 , 22(05) : 421 -428 . DOI: 10.16150/j.1671-2870.2023.05.002

Abstract

In 2022, the World Health Organization (WHO) proposed the 5th edition of the WHO Classification of Haematolymphoid Tumours (referred to as the 5th ed. WHO classification) based on the accumulated research results and clinical application progress in related fields after the revised 4th Edition of the WHO classification. Myelodysplastic neoplasms/syndrome (MDS) and acute myeloid leukemia (AML) in the 5th ed. edition of the WHO classification. In practice in WHO classification has major changes from the revised 4th, it is of great significance for clinical disease diagnosis and treatment, as well as disease registration and scientific research. This article is interpreted based on the fifth edition of the classification published in the journal Leukemia and online ahead of print version on the official website of the International Agency for Research on Cancer.

参考文献

[1] KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
[2] HUBER S, HAFERLACH T, MüLLER H, et al. MDS subclassification-do we still have to count blasts?[J]. Leukemia, 2023, 37(4):942-945.
[3] SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO Classification of Tumours of Haematopoietic and LymphoidTissues[M]. 4th ed.Lyon: IARC, 2017.
[4] CREE I A. The WHO Classification of Haematolymphoid Tumours[J]. Leukemia, 2022, 36(7):1701-1702.
[5] MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2):157-170.
[6] BERNARD E, NANNYA Y, HASSERJIAN R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10):1549-1556.
[7] WHO Classification of Tumours Editorial Board. Haematolymphoid tumours[M]// WHO classification of tumours series. 5th ed. Lyon (France): International Agency for Research on Cancer, 2022.
[8] ESTEY E, HASSERJIAN RP, D?HNER H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal[J]. Blood, 2022, 139(3):323-332.
[9] ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228.
[10] SOUPIR C P, VERGILIO J A, DAL CIN P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis[J]. Am J Clin Pathol, 2007, 127(4):642-650.
[11] TARLOCK K, LAMBLE A J, WANG Y C, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group[J]. Blood, 2021, 138(13):1137-1147.
[12] GAO Y, JIA M, MAO Y, et al. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia[J]. Am J Clin Pathol, 2022, 157(5):691-700.
[13] DI GIACOMO D, LA STARZA R, GORELLO P, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia[J]. Blood, 2021, 138(9):773-784.
[14] WICK N, HITTO I, WELDER D, et al. Acute myeloid leukemia with RAM immunophenotype presenting with extensive mesenteric and retroperitoneal lymphadenopathy: A case report and review of the literature[J]. Leuk Res Rep, 2021, 17:100287.
文章导航

/